Quiet®

Pharmacological properties

The pharmacologically active components of the drug are guaifenesin and an extract from medicinal plants, which has a predominantly calming effect. the calming effect of the extract is combined with the muscle relaxant effect of guaifenesin (relaxes smooth muscles).

Guaifenesin is rapidly absorbed in the digestive tract, metabolized in the liver by conjugation with glucuronic acid, and excreted in the form of inactive metabolites, mainly in the urine.

Indications

A mild form of neurasthenia, especially if it is accompanied by anxiety, fear, sadness, restlessness, irritability, dullness of attention or tiredness, sleep disturbance, insomnia, exhaustion or neurotic memory impairment. maintenance therapy for migraine, headache caused by nervous tension, vascular psychosomatic disorders with neurocircular asthenia, neuromuscular irritability, pain in the face, with menopause. functional diseases of the digestive tract (dyspeptic syndrome, irritable bowel syndrome). psychosomatic dermatosis, accompanied by itching (urticaria, atopic eczema).

Application

Usually, 5 ml (1 teaspoon) of the drug is prescribed 3 times a day. if necessary, the dose can be increased to 10 ml 3 times a day or reduced to 2.5 ml in the morning and afternoon and 5 ml in the evening. the dose can be changed in accordance with the condition of the patient.

The interval between doses of individual doses should be from 4 to 6 hours. The maximum daily dose is 30 ml.

The drug can be mixed with drinks (juice, tea).

Contraindications

Hypersensitivity to the active components or excipients of the drug, myasthenia gravis, epilepsy.

Side effects

Quiet is well tolerated by patients, but the following adverse reactions are possible:

from the nervous system: rarely - dizziness, drowsiness;

from the digestive tract: rarely - nausea, vomiting, cramping, heartburn, diarrhea or constipation;

on the part of the skin: rarely - exanthema, itching;

from the musculoskeletal system: rarely - mild muscle weakness;

general disorders: rarely fatigue.

special instructions

During the use of the drug, patients, especially with fair skin, should avoid prolonged exposure to ultraviolet radiation (sunbathing, tanning beds, diathermy).

Use the drug with caution in severe liver diseases, intoxication with substances that depress the central nervous system.

The drug contains 11.72 vol.% Ethanol, one dose (2.5 ml) contains 0.231 g of ethanol, which must be taken into account when used during pregnancy, breastfeeding, children and risk groups (patients with liver diseases, epilepsy, patients with alcoholism) .

The drug is contraindicated in individuals with rare hereditary fructose intolerance or glucose-galactose malabsorption.

Use during pregnancy and lactation

Pregnancy. Studies of reproductive functions during the use of the drug have not been carried out; the safety of the drug during pregnancy has not been established. In this regard, Quiet can be prescribed during pregnancy only in exceptional cases. Before its use, especially in the first trimester, it is necessary to assess the ratio of the potential risk to the fetus and the expected benefits for the pregnant woman.

Lactation. It is not known whether guaifenesin and other active components of the drug are excreted in breast milk, so the potential risk of the effect of the drug on the baby and the possible benefits for the mother should be carefully weighed.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms.Due to the fact that Quiet contains ethanol and guaifenesin, its use can lead to inhibition of the reaction, which is manifested individually in each patient. Therefore, it is worthwhile to refrain from potentially dangerous activities that require increased attention, such as driving vehicles or working with other mechanisms.

Children. The drug is used in children aged 12 years.

Interactions

Guaifenesin enhances the analgesic effect of paracetamol and acetylsalicylic acid and enhances the effect of alcohol and other substances that inhibit the central nervous system. central muscle relaxants can enhance the unwanted effects of guaifenesin, especially muscle weakness.

Perforated St. Johns wort can cause the induction of isoenzymes 3A4, 1A2 and 2C9 of cytochrome P450, which can weaken the effect of other drugs used simultaneously that are metabolized by these isoenzymes. The indicated action may also be due to the ability to induce the intestinal transport system P-glycoprotein. This interaction was first detected in healthy volunteers with the simultaneous use of indinavir and perforated hypericum. It can also be expected that this interaction also occurs with other retroviral protease inhibitors (aprenavir, nelfinavir, ritonavir, saquinavir), as well as non-nucleotide reverse transcriptase inhibitors (delaverdine, efavirenz, nevirapine), which are used in the treatment of HIV-1-positive patients. With the combined use of antiretroviral drugs and hypericum perforated, their action is weakened with the possible occurrence of resistance. Therefore, St. Johns wort is not used simultaneously with these drugs.

Significant clinical interactions with St. Johns wort were also observed while taking cyclosporine, digoxin and warfarin. The interaction can lead to a decrease in the concentration of drugs in the blood plasma and, accordingly, to a decrease in the severity of the therapeutic effect. Therefore, St. Johns wort can not be used with cyclosporine. If the patient uses cyclosporine, then it is necessary to cancel the intake of St. Johns wort and, given the level of cyclosporin in the blood plasma, to correct the dosage of cyclosporin.

The simultaneous use of St. Johns wort with digoxin or warfarin is not recommended. If the appointment of St. Johns wort is necessary, they monitor the level of digoxin in the blood plasma or control the prothrombin index during treatment with warfarin, the dose should be changed accordingly. When the dose of warfarin or digoxin is increased, the dose of St. Johns wort is not changed.

Perforated St. Johns wort can significantly reduce the effect of theophylline, so the simultaneous use is not recommended. If it is necessary to take St. Johns wort, it is required to control the theophylline level in the blood plasma and, if necessary, to correct the dose of theophylline without changing the dose of St. Johns wort.

Concomitant use with oral contraceptives can cause menstrual irregularities, bleeding, as well as a decrease in the effectiveness of the drug. Therefore, the simultaneous use of St. Johns wort and oral contraceptives is not recommended.

Combination therapy with amitriptyline is not recommended.

Influence on the results of laboratory tests.

Guaifenesin can cause false-positive diagnostic test results in which 5-hydroxyindoleacetic acid is determined (photometric method using nitrosonaphthol as a reagent) and vanillin mandelic acid in the urine. Therefore, treatment with Quiet should be stopped 48 hours before urine collection for this analysis.

Overdose

At first it is manifested by depression of central nervous system, drowsiness. later, these symptoms may be accompanied by nausea, mild muscle weakness, joint pain and a feeling of heaviness in the stomach.

The treatment is exclusively symptomatic and corresponds to the general principles of treatment in case of an overdose. There is no specific antidote.

Storage conditions

At a temperature not exceeding 25 ° C. do not freeze. Keep out of the reach of children.